[A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?]
- PMID: 29039837
- DOI: 10.17116/terarkh2017899100-103
[A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?]
Abstract
The paper considers a clinical example of current therapy for idiopathic pulmonary arterial hypertension in a female patient with its clinical deterioration. It shows the tactics of switching from one drug (bosentan) to others (macitentan) within in the same pathogenetic therapy group (endothelin receptor antagonists). The latest pulmonary hypertension classification (Nice, 2013) is presented. The current strategies of pathogenetic therapy for pulmonary hypertension are discussed.
В статье рассматривается клинический пример современной терапии идиопатической легочной артериальной гипертензии у пациентки с клиническим ухудшением течения заболевания. Показана тактика замены одного препарата (бозентан) другим (мацитентан) в рамках одной группы патогенетической терапии (антагонисты рецепторов эндотелина). Представлена последняя классификация легочной гипертензии (Ницца, 2013 г.) Обсуждаются вопросы современной стратегии патогенетической терапии легочной гипертензии.
Keywords: bosentan; combined therapy; idiopathic pulmonary arterial hypertension; macitentan; riociguat.
Similar articles
-
[A clinical case of long-term macitentan therapy in a female patient with idiopathic pulmonary hypertension].Ter Arkh. 2016;88(12):88-93. doi: 10.17116/terarkh2016881288-93. Ter Arkh. 2016. PMID: 28139566 Russian.
-
Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension.Am J Physiol Regul Integr Comp Physiol. 2016 Oct 1;311(4):R721-R726. doi: 10.1152/ajpregu.00475.2015. Epub 2016 Aug 17. Am J Physiol Regul Integr Comp Physiol. 2016. PMID: 27534881 Review.
-
Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.Lancet Respir Med. 2016 May;4(5):361-71. doi: 10.1016/S2213-2600(16)30019-4. Epub 2016 Apr 8. Lancet Respir Med. 2016. PMID: 27067479 Clinical Trial.
-
Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.Am J Cardiovasc Drugs. 2018 Feb;18(1):1-11. doi: 10.1007/s40256-017-0260-1. Am J Cardiovasc Drugs. 2018. PMID: 29280064 Free PMC article. Review.
-
Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study.J Heart Lung Transplant. 2017 May;36(5):509-519. doi: 10.1016/j.healun.2016.12.012. Epub 2016 Dec 24. J Heart Lung Transplant. 2017. PMID: 28190787 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical